#NephJC Transcript
Healthcare social media transcript of the #NephJC hashtag.
– ().
See #NephJC Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | Michelle Rheault @rheault_m RT @NephJC: #NephJC tonight Article: https://t.co/NGzyai8qC4 Summary: https://t.co/ioILbQwy6U #VisualAbstract https://t.co/iSa1ZEm09Y |
 | Silvi Shah, MD, MS @silvishah RT @NephJC: #NephJC tonight Article: https://t.co/NGzyai8qC4 Summary: https://t.co/ioILbQwy6U #VisualAbstract https://t.co/iSa1ZEm09Y |
 | Matthew Sparks, MD @Nephro_Sparks RT @NephJC: #NephJC tonight Article: https://t.co/NGzyai8qC4 Summary: https://t.co/ioILbQwy6U #VisualAbstract https://t.co/iSa1ZEm09Y |
 | Daniel Coyne @DrDanMO RT @Maximal_Change: Really looking forward to this #nephJC tonight! Hope to see old and new friends there and learn something new! https://t.co/Ig6e3cJqgs |
 | Joel M. Topf, MD FACP @kidney_boy RT @NephJC: #NephJC tonight Article: https://t.co/NGzyai8qC4 Summary: https://t.co/ioILbQwy6U #VisualAbstract https://t.co/iSa1ZEm09Y |
 | Owen Albin @owenralb RT @NephJC: #NephJC tonight Article: https://t.co/NGzyai8qC4 Summary: https://t.co/ioILbQwy6U #VisualAbstract https://t.co/iSa1ZEm09Y |
 | Bea Concepcion @KidneyBea_n RT @NephJC: #NephJC tonight Article: https://t.co/NGzyai8qC4 Summary: https://t.co/ioILbQwy6U #VisualAbstract https://t.co/iSa1ZEm09Y |
 | Akbar. @Kidneyisland RT @NephJC: #NephJC tonight Article: https://t.co/NGzyai8qC4 Summary: https://t.co/ioILbQwy6U #VisualAbstract https://t.co/iSa1ZEm09Y |
 | Andrew M. Ibrahim MD, MSc (He/Him) @AndrewMIbrahim RT @NephJC: #NephJC tonight Article: https://t.co/NGzyai8qC4 Summary: https://t.co/ioILbQwy6U #VisualAbstract https://t.co/iSa1ZEm09Y |
 | Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 Use your #patientvoice and contact Congress Tell them funding #ckd research is a #publichealth priority https://t.co/aQjfkVRZDH #nephJC |
 | The George Institute for Global Health @georgeinstitute RT @NephJC: #NephJC tonight Article: https://t.co/NGzyai8qC4 Summary: https://t.co/ioILbQwy6U #VisualAbstract https://t.co/iSa1ZEm09Y |
 | Edgar V. Lerma 🇵🇭 @edgarvlermamd Canagliflozin and CV & Renal Events in Type 2 DM #VisualAbstract #NephJC #Nephpearls 👉🏼 https://t.co/zm8nraaxg1 https://t.co/E79nGygral |
 | Sabrina Natarajan @ottawamarble Hey @mjdeschenes hope you're able to participate tonight @9pm! https://t.co/8oZrt2QapE |
 | George Clinical @george_clinical RT @NephJC: #NephJC tonight Article: https://t.co/NGzyai8qC4 Summary: https://t.co/ioILbQwy6U #VisualAbstract https://t.co/iSa1ZEm09Y |
 | Mana @manasigh RT @edgarvlermamd: Canagliflozin and CV & Renal Events in Type 2 DM #VisualAbstract #NephJC #Nephpearls 👉🏼 https://t.co/zm8nraaxg1 https://t.co/E79nGygral |
 | Carlos Fernandez, PharmD @rojasfec This pictorial will save some reading.... :-) https://t.co/eT8r7Q7c5q |
 | Swapnil Hiremath @hswapnil@bsky.social @hswapnil @RossNesbit @drpaddymark @paulphel @RichardHaynes3 Hope you are coming to #NephJC tonight? |
 | Tim Leung @tsleung RT @kidney_boy: CANVAS release candidate 2 (now in technicolor) #NephJC Feedback welcome https://t.co/GpOYtSrs3E |
 | Nephrology Journal Club @NephJC Just over an hour left for tonight's #NephJC Not too late to read the article or the summary. Or just use the #VisualAbstract to wing it! |
 | Vlado Perkovic @VladoPerkovic @NephJC @kidney_boy @NEJM @georgeinstitute Nice infographic. Dont forget renal and heart failure effects if wish to fully balance risks and benefits #nephjc |
| Vlado Perkovic @VladoPerkovic RT @kidney_boy: #NephJC Definitive renal outcomes in the Canagliflozin and Renal Endpoints in DM with Estab. Nephropathy Clinical Eval. trial (CREDENCE) |
 | Reny Duarsa @Renaladdict RT @edgarvlermamd: Canagliflozin and CV & Renal Events in Type 2 DM #VisualAbstract #NephJC #Nephpearls 👉🏼 https://t.co/zm8nraaxg1 https://t.co/E79nGygral |
| Nephrology Journal Club @NephJC T - 10 minutes. Anyone here? #nephjc |
 | Phillip Madonia @PMNax2 Phillip Madonia Private practice BHam AL Mostly will be lurking #nephjc https://t.co/YRDBcxC7yq |
| Nephrology Journal Club @NephJC @PMNax2 hey Phil! nice to see you. We will be live soon #nephjc |
 | Ross Nesbit @RossNesbit Ross Nesbit, UT Nephrology, Knoxville, TN. #nephjc |
| Ross Nesbit @RossNesbit Happy to see @PMNax2 here tonight #nephjc |
| Joel M. Topf, MD FACP @kidney_boy Joel Topf, co-founder of #NephJC, I'm just looking for an hour without dog nephrotic syndrome tweets #nephjc |
| Matthew Sparks, MD @Nephro_Sparks Matt Sparks, @DukeKidney APD @KIDNEYcon Edu Director. In and out tonight #NephJC |
| Nephrology Journal Club @NephJC Welcome to the oh-so-sweet edition of #NephJC on #CANVAS Summary here: https://t.co/ioILbQeWIk |
| Phillip Madonia @PMNax2 Very happy to be here #nephjc https://t.co/52ZnwJak41 |
| Nephrology Journal Club @NephJC Hey Joel, Matt and Ross (and Phil)! #nephjc |
| Nephrology Journal Club @NephJC Please introduce yourself (even if you plan to lurk) and disclose any conflicts of interests (CoI) #NephJC |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil Swapnil Hiremath, #NephJC cofounder from @OttawaRenal @OttawaHospital No CoI https://t.co/DIBtyppbxe |
 | Timothy Yau @Maximal_Change Tim Yau from @WUSTLNephrology, no COI #nephjc |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil Just in time for #NephJC https://t.co/NXCE6YdLoh |
| Nephrology Journal Club @NephJC Remember to add #NephJC to all your tweets Or just use @tchatio ie go to https://t.co/4zRxyflhEJ |
| Timothy Yau @Maximal_Change Tim Yau from @WUNephrology, no COI #nephjc |
 | William Beaubien-Souligny @WBeaubien William Beaubien-Souligny, Nephrology fellow in Montreal #nephjc |
| Nephrology Journal Club @NephJC @Maximal_Change Hi Tim! Nice video of #NephJC crew on 2ajkdonline - thanks! |
| Nephrology Journal Club @NephJC @WBeaubien welcome William! #nephjc |
 | Daniel Edmonston @DanEdmonston Daniel Edmonston. @DukeKidney fellow. On vacation so mostly lurking. Obviously not COI. #NephJC |
| Vlado Perkovic @VladoPerkovic @NephJC Nephrologist and trialist. Co-author on paper. Funding from Janssen, also consulted for BI and AZ. look forward to the discussion #nephjc |
| Edgar V. Lerma 🇵🇭 @edgarvlermamd Edgar Lerma, Chicago-based Nephrologist #NephJC https://t.co/6yxme5YBjG |
| Michelle Rheault @rheault_m @NephJC Michelle Rheault here. Ped Neph UMN. COI: I don't see (much) type 2 diabetes. Mostly lurking #NephJC |
 | Hector Madariaga, MD FASN 🇲🇽 @HecmagsMD Hector Madariaga, from #patriotsnation. No COI. Hi, everyone! #nephjc |
| Timothy Yau @Maximal_Change @HecmagsMD How's the family Hector? #nephjc |
| Matthew Sparks, MD @Nephro_Sparks RT @NephJC: Welcome to the oh-so-sweet edition of #NephJC on #CANVAS Summary here: https://t.co/ioILbQeWIk |
 | Katalin Susztak @KSusztak #nephjc Hello Katalin is here |
| Bea Concepcion @KidneyBea_n Bea Concepcion from @VUMCKidney #NSMC no COI, hello everyone! #nephjc |
 | Poyan Mehr @poyanmehr Ali Poyan Mehr, Boston no COI #NephJC |
| Nephrology Journal Club @NephJC Hecs, Michelle, Edgar, Katalin, Bea - and Daniel, Ali - nice show #nephjc |
| Edgar V. Lerma 🇵🇭 @edgarvlermamd SGLT2 inhibitors: Origin #NephJC #Nephpearls 👉🏼 https://t.co/HKVWiv8qwm https://t.co/MWuCyX8FPV |
| Timothy Yau @Maximal_Change @KidneyBea_n @VUMCKidney Hey Bea, great to see you :) #nephjc |
| Nephrology Journal Club @NephJC This is Swapnil Hiremath @hswapnil from Ottawa hosting tonight. Expect a packed house to the #NephJC signal https://t.co/VmTIveuUBF |
 | Gates Colbert, MD @DoctorGates Dallas Nephrologist. #NSMC 2017 intern. Ready to discuss CANVAS. #nephjc |
| Hector Madariaga, MD FASN 🇲🇽 @HecmagsMD @Maximal_Change Hi Tim! They are doing great. Thanks for asking. How about your family? Happy Father's Day! #NephJC |
| Joel M. Topf, MD FACP @kidney_boy RT @VladoPerkovic: @NephJC @kidney_boy @NEJM @georgeinstitute Nice infographic. Dont forget renal and heart failure effects if wish to fully balance risks and benefits #nephjc |
| Nephrology Journal Club @NephJC @DoctorGates Congrats on the ASH certification! #nephjc |
| Matthew Sparks, MD @Nephro_Sparks @HecmagsMD Hi Hecs #NephJc |
| Timothy Yau @Maximal_Change @HecmagsMD They're doing well, getting bigger and bigger :) #nephjc |
 | ChristosArgyropoulos MD, PhD PharmanukerInChief @ChristosArgyrop Christos Argyropoulos, University of New Mexico Nephrology #NephJC No COI (except disagreeing about the outcome of #Nephmadness) |
 | Nikhil Shah MBBS DNB(IM, Neph)🇨🇦 @dr_nikhilshah #nephjc Whew! Made it. But only lurking! Nikhil Shah Nephrologist. No CoI. Glad to be back even to lurk. |
 | Arvind Canchi (Conjeevaram)🇮🇳 @arvindcanchi #NephJC Arvind Canchi, Nephrologist from Bangalore, no COI |
| Nephrology Journal Club @NephJC Any authors in the house from @george_clinical ? @VladoPerkovic will join later, maybe @BruceNeal1 ? #NephJC |
| Hector Madariaga, MD FASN 🇲🇽 @HecmagsMD @Nephro_Sparks Hi, boss! 👋👋 hope all is well! #nephjc |
| Ross Nesbit @RossNesbit @ChristosArgyrop This view should never be let go #blueribbonfail #nephjc |
| Timothy Yau @Maximal_Change @DoctorGates Congrats! #nephjc |
| Nephrology Journal Club @NephJC Arvind, Nikhil, Tulun, Christos (of course) #nephjc |
| Nephrology Journal Club @NephJC We are discussing this @NEJM RCT, funded by @JanssenUS & carried out by @georgeinstitute https://t.co/NGzyaiq1tC #NephJC |
| Nephrology Journal Club @NephJC Warm up question T0 do you use SGLT2 inhibitors already? if yes, for whom? If no, why not? #NephJC |
| Silvi Shah, MD, MS @silvishah Hi this is Silvi from Cincinnati no Coi #NephJC |
| Vlado Perkovic @VladoPerkovic @NephJC @george_clinical @BruceNeal1 I am here! Looking forward to the discussion #NephJC |
 | rob @renalpolitics rob rope, stanford renal fellow for 3..2.... howdy, never any coid #nephjc |
| Joel M. Topf, MD FACP @kidney_boy Author in the house! RT @VladoPerkovic: @NephJC @george_clinical @BruceNeal1 I am here! Looking forward to the discussion #NephJC |
| Nephrology Journal Club @NephJC @VladoPerkovic @NephJC @george_clinical @BruceNeal1 fabulous - watch your manners guys! #nephjc |
| Nephrology Journal Club @NephJC Welocme Silvi and Rob! #nephjc |
| Timothy Yau @Maximal_Change @NephJC Have not personally started it on a patient, but have several patients with relatively preserved GFR on them from endocrine #nephjc |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil RT @NephJC: Warm up question T0 do you use SGLT2 inhibitors already? if yes, for whom? If no, why not? #NephJC |
| Ross Nesbit @RossNesbit T0: I've come across a few so far, mostly in proteinuria referrals that have preserved GFR to that point. Haven't started one #nephjc |
| Silvi Shah, MD, MS @silvishah I haven't used sglt 2 inhibitors so far #nephjc |
| Joel M. Topf, MD FACP @kidney_boy Dr. Vlado Perkovic (@VladoPerkovic ) has only has only 568 followers. Let's pump that up! #nephjc |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil @NephJC Once: with HT and uncontrolled DM. Locally endos still quite wary (DKA) #nephjc |
| ChristosArgyropoulos MD, PhD PharmanukerInChief @ChristosArgyrop @NephJC Yes I do - if/when insurance allows and the copay manageable. eGFR 45-60 (empa), eGFR>60 indifferent to choice of SGLT2i #Nephjc |
| Timothy Yau @Maximal_Change @NephJC Some have mentioned there is pre-authorization and insurance issues starting. Anyone run into that yet for this class? #nephjc |
| The George Institute for Global Health @georgeinstitute RT @NephJC: We are discussing this @NEJM RCT, funded by @JanssenUS & carried out by @georgeinstitute https://t.co/NGzyaiq1tC #NephJC |
| Nephrology Journal Club @NephJC RT @kidney_boy: Dr. Vlado Perkovic (@VladoPerkovic ) has only has only 568 followers. Let's pump that up! #nephjc |
| Edgar V. Lerma 🇵🇭 @edgarvlermamd Currently FDA approved SGLT2 inhibitors #NephJC #Nephpearls 👉🏼 https://t.co/cKcWms9j0Y https://t.co/jd1EHUyvRD |
| Nephrology Journal Club @NephJC @khaled1409 hey Khaled, welcome (what time there?) #nephjc |
| Joel M. Topf, MD FACP @kidney_boy Forget preserved GFR, I only use them patients with a full complement of toes! #nephjc |
| Timothy Yau @Maximal_Change RT @kidney_boy: Forget preserved GFR, I only use them patients with a full complement of toes! #nephjc |
| rob @renalpolitics I had residency patient x 1 on canafloglozin early on (from outside provider) on prior to weight loss fixing his diabetes #nephjc |
 | Dr. Jordan Weinstein @drjjw Hi all. Have used in a large number of patients #NephJC |
| Silvi Shah, MD, MS @silvishah @NephJC Not yet- now I think why? Maybe did not get trained in it but will do soon #nephJC |
| Nephrology Journal Club @NephJC @drjjw welcome Jordan! Presumably in diabetic patients? #nephjc |
| Nephrology Journal Club @NephJC T0 follow up: Have you seen any patient with SGLT2 & a complication? (Eg DKA or urogenital infxn) #NephJC |
| Timothy Yau @Maximal_Change @drjjw Hi Jordan! You start mainly for CV protection, glycemic control, or both? #nephjc |
| Nephrology Journal Club @NephJC RT @ChristosArgyrop: @NephJC Yes I do - if/when insurance allows and the copay manageable. eGFR 45-60 (empa), eGFR>60 indifferent to choice of SGLT2i #Nephjc |
| Dr. Jordan Weinstein @drjjw @NephJC Yes, only in diabetes so far. #NephJC |
| Gates Colbert, MD @DoctorGates I'm a fan of SGLT2i - interesting trials so far. Don't usually start them myself. PCPs usually take ownership of DM mgmt locally #nephjc |
 | Pablo Garcia @PabloGarciaMD Pablo Garcia from New Brunswick, NJ. No CoI. #NSMC intern 2017 #nephjc |
| Nephrology Journal Club @NephJC #NephJC https://t.co/a8KFvWcLun |
| Joel M. Topf, MD FACP @kidney_boy How long until we see an attempt to get approval for weight loss? #nephjc |
| Timothy Yau @Maximal_Change @PabloGarciaMD Hey Pablo, how've you been? #nephjc |
| Edgar V. Lerma 🇵🇭 @edgarvlermamd SGLT2 inhibitors: Mechanism #NephJC #Nephpearls 👉🏼 https://t.co/HKVWivq1nU https://t.co/sTdvvHXaal |
| Nephrology Journal Club @NephJC so far, he says! RT @drjjw: @NephJC Yes, only in diabetes so far. #NephJC |
| Nephrology Journal Club @NephJC @PabloGarciaMD Pablo! nice to see you back #nephjc |
| Michelle Rheault @rheault_m @NephJC T0: I've never used SGLT2 inhibitors. But paying attention as type 2 diabetes is increasing in adolescents. #NephJC https://t.co/4l1HTq0m7j https://t.co/ymfjAgD8b8 |
 | Detox Relay @DetoxRelay RT @kidney_boy: How long until we see an attempt to get approval for weight loss? #nephjc |
| Joel M. Topf, MD FACP @kidney_boy I am regularly writing in may consult notes to start them. Have had a lot of trouble with insurance cos when I tried myself. #nephjc |
| Timothy Yau @Maximal_Change @kidney_boy Any studies on how many calories in sugar you pee out/day on these drugs? #nephjc |
| Sabrina Natarajan @ottawamarble Sabrina, EM pharmacist in Ottawa. SGLT2i notable in my practice because we are seeing cases of associated euglycemic DKA #NephJC |
| Ross Nesbit @RossNesbit @kidney_boy An attempt? Surely that lobbying is ongoing...if DDAVP can get nocturia indication, anything is possible. #nephjc |
 | Kenar Jhaveri @kdjhaveri @silvishah Same here #nephJC |
| Nephrology Journal Club @NephJC @ottawamarble welcome, Sabrina! #nephjc |
| Nephrology Journal Club @NephJC @kdjhaveri @silvishah hi Kenar! #nephjc |
| Vlado Perkovic @VladoPerkovic @kidney_boy some of the early development was for weight loss. Will be interesting to see if it is picked up again #nephjc |
| Arvind Canchi (Conjeevaram)🇮🇳 @arvindcanchi @NephJC Follow pts who are already on it prescribed by endo #nephjc |
| Nephrology Journal Club @NephJC RT @VladoPerkovic: @kidney_boy some of the early development was for weight loss. Will be interesting to see if it is picked up again #nephjc |
| Dr. Jordan Weinstein @drjjw @Maximal_Change I start for both. I have found I like treating diabetes more than I thought. #Nephjc |
| Nephrology Journal Club @NephJC OK - some, not a lot of usage. Lets start with CANVAS now #nephjc |
| Nephrology Journal Club @NephJC RT @rheault_m: @NephJC T0: @NephJC T0: I've never used SGLT2 inhibitors. But paying attention as type 2 diabetes is increasing in adolescents. #NephJC https://t.co/4l1HTq0m7j https://t.co/ymfjAgD8b8 |
| Nephrology Journal Club @NephJC Lots of additional material at the @georgeinstitute website freely available https://t.co/swGfh9uGqn #NephJC |
| The George Institute for Global Health @georgeinstitute RT @NephJC: Lots of additional material at the @georgeinstitute website freely available https://t.co/swGfh9uGqn #NephJC |
| Nephrology Journal Club @NephJC T1: methods Let's dive in. CANVAS program = CANVAS + CANVAS-R Everyone OK with how that played out? #NephJC https://t.co/WDhjjq2Ia4 |
| Edgar V. Lerma 🇵🇭 @edgarvlermamd SGLT2 inhibitors ➡️ Weight Loss #NephJC #Nephpearls 👉🏼 https://t.co/HKVWivq1nU https://t.co/l2XYSYiVtp |
| ChristosArgyropoulos MD, PhD PharmanukerInChief @ChristosArgyrop No DKA - urogenital sure #NephJC (but note my endo colleagues careful about T1 vs T2 pathophys and we share clinic space & apts #NephJC https://t.co/bosfckuBOb |
| Joel M. Topf, MD FACP @kidney_boy since they unblinded part of their cohort, they started a second trial. Sounds like the right way to handle it #nephjc |
| Nephrology Journal Club @NephJC T1: plan was for CANVAS phase 1 f/b expansion to phase 2 with 14,000 Interim results used sponsor, so 1/2 #NephJC https://t.co/eElLkPVmPb |
| Nephrology Journal Club @NephJC T1: contd: plan changed to add-on CANVAS-R. See https://t.co/lC3drl8996 for details #NephJC https://t.co/yQ4PaX1vCS |
| Joel M. Topf, MD FACP @kidney_boy after you fire the guy who unblinded the trial early. #nephjc |
| Timothy Yau @Maximal_Change @NephJC The transition from CANVAS to CANVAS-R was interesting but since the data was unblinded, appropriate #nephjc |
| ChristosArgyropoulos MD, PhD PharmanukerInChief @ChristosArgyrop @NephJC Did not like the unblidning. Also CANVAS and CANVAS-R done over different periods (? secular trends) #Nephjc |
 | John Neary @jddneary @NephJC #nephjc |
| Nephrology Journal Club @NephJC Did you sense some unhappiness with the unblinding for approval? Or a pragmatic decision? #nephjc |
| Edgar V. Lerma 🇵🇭 @edgarvlermamd SGLT2 inhibitors: Cardioprotective #NephJC #Nephpearls 👉🏼 https://t.co/HKVWiv8qwm https://t.co/WZzN7kOONy |
| Ross Nesbit @RossNesbit @kidney_boy Agree completely with the first thought...hard not to agree with this one. A teaching moment #nephjc |
| Edgar V. Lerma 🇵🇭 @edgarvlermamd SGLT2 inhibitors: Renoprotective #NephJC #Nephpearls 👉🏼 https://t.co/HKVWivq1nU https://t.co/hq6j58AG7g |
| Nephrology Journal Club @NephJC RT @RossNesbit: @kidney_boy Agree completely with the first thought...hard not to agree with this one. A teaching moment #nephjc |
| Nephrology Journal Club @NephJC #NephJC https://t.co/RPoCAX3P3k |
| Daniel Edmonston @DanEdmonston @edgarvlermamd Is the weight loss effect independent of diuretic effect? #nephjc |
| Nephrology Journal Club @NephJC #NephJC https://t.co/dspgmOrrjh |
| Nephrology Journal Club @NephJC T1: Population type 2 DM with GFR > 30 Age > 30 with CV dz or Age > 50 with 2 or more CV risk factors #NephJC |
| Joel M. Topf, MD FACP @kidney_boy @DanEdmonston @edgarvlermamd great question, how would you determine that? #nephjc |
| Silvi Shah, MD, MS @silvishah RT @NephJC: #NephJC https://t.co/dspgmOrrjh |
| Timothy Yau @Maximal_Change @DanEdmonston @edgarvlermamd One could argue net negative calories b/c of the glucosuria. #nephjc |
| Sabrina Natarajan @ottawamarble We've noted more 20 cases of euglycemic DKA in the last year at our hospital. Some Dx late so maybe more misdiagnosed. #NephJC https://t.co/UeCXvdjIsa |
| Ross Nesbit @RossNesbit @Maximal_Change Very intrigued by this idea...waiting on that glucose/caloric calculation... #nephjc |
| Joel M. Topf, MD FACP @kidney_boy Vote in my micro albumin poll before Swapnil gives you the answer: https://t.co/YZUHlrwdag #nephjc |
| Gates Colbert, MD @DoctorGates Weight loss appears sustained. Would only be temporary if fluid losses alone. Additionally a SE is thirst from vol depletion #NephJC https://t.co/NwMF2GZgK0 |
| Nephrology Journal Club @NephJC T1: non-inferiority design, mostly from FDA requireemnt to show CV safety (after rosiglitazone mess) https://t.co/6pF6hdPCyF #nephjc |
| Timothy Yau @Maximal_Change @RossNesbit Theoretically shouldn't be too hard to do. In old days before IRB, I'd take the drug, collect my urine for 24 hours #nephjc |
| Matthew Sparks, MD @Nephro_Sparks Im back. #nephjc |
| Dr. Jordan Weinstein @drjjw @ottawamarble Always strange to me that no prospective trials identified the DKA risk yet many cases found in postmarketing #NephJC |
| Daniel Edmonston @DanEdmonston @Maximal_Change @edgarvlermamd True. The speed of weight loss may be helpful. It could be like marketing furosemide as a weight loss drug... #NephJC |
| ChristosArgyropoulos MD, PhD PharmanukerInChief @ChristosArgyrop @DoctorGates Not sure I agree with that - this is why we put ppl with CHF on Lasix :) #Nephjc |
| Nephrology Journal Club @NephJC @drjjw @ottawamarble this one did (coming up later) #nephjc |
| Timothy Yau @Maximal_Change @RossNesbit measure glucose concentration, multiply by urine volume, and find out how many calories in 1 gram of glucose. #nephjc |
| Joel M. Topf, MD FACP @kidney_boy @Maximal_Change @RossNesbit the glycosuria would be higher for poorer glycemic control. No? #nephjc |
| Matthew Sparks, MD @Nephro_Sparks @drjjw @ottawamarble watching them closer?? #DKAWatch #nephjc |
| Timothy Yau @Maximal_Change RT @drjjw: @ottawamarble Always strange to me that no prospective trials identified the DKA risk yet many cases found in postmarketing #NephJC |
| Nephrology Journal Club @NephJC T1: strict hierarchy of outcomes since CANVAS-R added in. Looks robust, agree? #NephJC https://t.co/Ii49HQCn7k |
| ChristosArgyropoulos MD, PhD PharmanukerInChief @ChristosArgyrop @drjjw @ottawamarble Shorter observation period + extending to populations not studied under the original trials #NephJC |
| John Neary @jddneary @NephJC I'm sick of multi-trial "programs", not to mention "key secondary endpoints" & all this nonsense. 1 trial, 1 analysis, 1 endpoint #nephjc |
| Timothy Yau @Maximal_Change @kidney_boy @RossNesbit Yes, it should. #nephjc |
| Nephrology Journal Club @NephJC T1: also note, though controls = placebo, background of std of care for glucose, BP, CV mgt etc #NephJC |
| Ross Nesbit @RossNesbit @kidney_boy @Maximal_Change Probably? Would this drive a higher UOP or beyond threshold of osmotic diuresis vs. diminishing returns? #nephjc |
| Nephrology Journal Club @NephJC RT @ChristosArgyrop: @drjjw @ottawamarble Shorter observation period + extending to populations not studied under the original trials #NephJC |
| ChristosArgyropoulos MD, PhD PharmanukerInChief @ChristosArgyrop Standard for these trials - remember the cinacalcet one? Similarhierarchical analysis #nephjc https://t.co/kBEihz05hn |
| Joel M. Topf, MD FACP @kidney_boy Does the hierarchy of outcomes protect against the risk of multiple comparisons? #nephjc |
| Nephrology Journal Club @NephJC @ChristosArgyrop @drjjw @ottawamarble and not unusual for less common side effects to be seen in phase 4 studies #nephjc |
| Edgar V. Lerma 🇵🇭 @edgarvlermamd SGLT2 inhibitors and DKA: Proposed mechanisms #SCM16 #Nephpearls #NephJC Photo credit: @HecmagsMD https://t.co/URiqj4D5ft |
| Arvind Canchi (Conjeevaram)🇮🇳 @arvindcanchi @NephJC Yes, two pts with prostatic abscesses. Difficult to treat. One Pt needed surgery and UTI kept recurring. #NephJC |
| Nephrology Journal Club @NephJC @kidney_boy Christos answered just before you asked! #telepathy #nephjc |
| Timothy Yau @Maximal_Change @RossNesbit @kidney_boy Maybe not as simple as I originally thought... #nephjc |
| Nephrology Journal Club @NephJC (Acknowledgment: Lot of material directly from @george_clinical website: https://t.co/swGfh9uGqn) #NephJC |
| Dr. Jordan Weinstein @drjjw @NephJC @ChristosArgyrop @ottawamarble Yes. But they are adjudicated inconsistently. No standardization. No blinding etc etc #Nephjc |
| Sabrina Natarajan @ottawamarble @Nephro_Sparks @drjjw Our pharms are def more aware and starting to screen earlier. Lots of pts misdiagnosed as sepsis early on #nephjc |
| Nephrology Journal Club @NephJC OK - lets move on to results since there are lots of them #nephjc |
| Dr. Jordan Weinstein @drjjw @ottawamarble @Nephro_Sparks I'm sorry but I don't buy it. #NephJC |
| William Beaubien-Souligny @WBeaubien RT @ottawamarble: @Nephro_Sparks @drjjw Our pharms are def more aware and starting to screen earlier. Lots of pts misdiagnosed as sepsis early on #nephjc |
| Timothy Yau @Maximal_Change @PabloGarciaMD doing well. busy as always, in a good way. you'll be a killer 3rd year resident. good luck with the fresh interns next week! #nephJC |
| ChristosArgyropoulos MD, PhD PharmanukerInChief @ChristosArgyrop Complicated - theoretically sequential procedure accounts for that (partially), but who decides on the order of testing? #nephjc https://t.co/0DYsdxwtHg |
| Nephrology Journal Club @NephJC T2: table 1, 14 years DM, ~ in 60s, mostly white, anything else strike you? #NephJC https://t.co/csFphxbLOU |
| Nephrology Journal Club @NephJC T2: also 30 countries, 667 sites. Let's acknowledge the Herculean task modern RCTs are to pull off! #NephJC https://t.co/Etlojq9Y3j |
| Matthew Sparks, MD @Nephro_Sparks @drjjw @ottawamarble @Nephro_Sparks curious... what are you suggesting? #nephjc |
 | Michael Fralick @FralickMike @drjjw @ottawamarble @Nephro_Sparks What would it take for you to "buy it"? #nephjc |
| George Clinical @george_clinical RT @NephJC: (Acknowledgment: Lot of material directly from @george_clinical website: (Acknowledgment: Lot of material directly from @george_clinical website: https://t.co/swGfh9uGqn) #NephJC |
| ChristosArgyropoulos MD, PhD PharmanukerInChief @ChristosArgyrop @NephJC Blood pressures were actually very decent #NephJC |
| Nephrology Journal Club @NephJC @FralickMike Hey Mike! great you could make it! (tweet your NEJM paper on this please) #nephjc |
| Nephrology Journal Club @NephJC RT @ChristosArgyrop: @NephJC Blood pressures were actually very decent #NephJC |
| George Clinical @george_clinical RT @NephJC: T2: T2: also 30 countries, 667 sites. Let's acknowledge the Herculean task modern RCTs are to pull off! #NephJC https://t.co/Etlojq9Y3j |
| Nephrology Journal Club @NephJC T2: lots of RAAS blockade, metformin in both arms looks good? #NephJC https://t.co/hSRQLSWA5q |
| Matthew Sparks, MD @Nephro_Sparks @NephJC @george_clinical impressive #NephJC |
| Michael Fralick @FralickMike @kidney_boy @drjjw @ottawamarble @Nephro_Sparks here's our work on the topic: https://t.co/spfkf6wLzn #nephjc |
| Nephrology Journal Club @NephJC RT @FralickMike: @kidney_boy @drjjw @ottawamarble @Nephro_Sparks here's our work on the topic: @kidney_boy @drjjw @ottawamarble @Nephro_Sparks here's our work on the topic: https://t.co/spfkf6wLzn #nephjc |
| Gates Colbert, MD @DoctorGates Small number of PVD - 20%, large CAD though. Possibly undetected PVD which could have confounded amputation surprise attack? #NephJC https://t.co/aIiRYCa0PF |
| William Beaubien-Souligny @WBeaubien RT @FralickMike: @kidney_boy @drjjw @ottawamarble @Nephro_Sparks here's our work on the topic: @kidney_boy @drjjw @ottawamarble @Nephro_Sparks here's our work on the topic: https://t.co/spfkf6wLzn #nephjc |
| The George Institute for Global Health @georgeinstitute RT @NephJC: T2: T2: lots of RAAS blockade, metformin in both arms looks good? #NephJC https://t.co/hSRQLSWA5q |
| Hector Madariaga, MD FASN 🇲🇽 @HecmagsMD @NephJC I've seen a couple of patients with orthostatic hypotension #NephJC |
| Joel M. Topf, MD FACP @kidney_boy How do you get 17% hx of nephropathy but only 7% with macroalbuminuria? #nephjc |
| Timothy Yau @Maximal_Change RT @kidney_boy: How do you get 17% hx of nephropathy but only 7% with macroalbuminuria? #nephjc |
| Sabrina Natarajan @ottawamarble @Nephro_Sparks @drjjw Acidosis nyd, finally responds to stopping SGLT2i. Certainly these pts have comorbid conditions and often on insulin #NephJC 1/2 |
| Arvind Canchi (Conjeevaram)🇮🇳 @arvindcanchi @NephJC @george_clinical I'm just worried that India has disappeared from the face of that map. #nephjc It did drift in to join & create Himalayas, perhaps under it? |
| Nephrology Journal Club @NephJC T2: so what did Cana do? Reduce sugar, BP and weight from figure 2 #NephJC https://t.co/95f2VJcALk |
| Ross Nesbit @RossNesbit @NephJC They did pretty well on finding a lot of non-proteinuric diabetics; 70% without is pretty darn good #nephjc |
| Nephrology Journal Club @NephJC RT @DoctorGates: Small number of PVD - 20%, large CAD though. Possibly undetected PVD which could have confounded amputation surprise attack? #NephJC https://t.co/aIiRYCa0PF |
| Sabrina Natarajan @ottawamarble @Nephro_Sparks @drjjw But no improvement in acidosis until drug d/c. But I have only seen 1 probable case myself. #NephJC 2/2 |
| Hector Madariaga, MD FASN 🇲🇽 @HecmagsMD RT @DoctorGates: Small number of PVD - 20%, large CAD though. Possibly undetected PVD which could have confounded amputation surprise attack? #NephJC https://t.co/aIiRYCa0PF |
| Timothy Yau @Maximal_Change @NephJC I feel like it does a little of everything - nothing that was huge, but everything moved in the right direction #nephjc |
| Nephrology Journal Club @NephJC RT @Maximal_Change: @NephJC I feel like it does a little of everything - nothing that was huge, but everything moved in the right direction #nephjc |
| Phillip Madonia @PMNax2 RT @RossNesbit: @NephJC They did pretty well on finding a lot of non-proteinuric diabetics; 70% without is pretty darn good #nephjc |
| Vlado Perkovic @VladoPerkovic @kidney_boy nephropathy is an investigator check box- macroalbuminuria measured at screening visit #NephJC |
| ChristosArgyropoulos MD, PhD PharmanukerInChief @ChristosArgyrop @kidney_boy 1. About 40%-50% of DKD in modern era will be minimally proteinuric 2. RAASi work #NephJC https://t.co/OXt1VhmjRt (for 1st point) |
| Timothy Yau @Maximal_Change @NephJC I should caveat that with the amputation issue of course. #nephjc |
| Joel M. Topf, MD FACP @kidney_boy @VladoPerkovic may need to take the investigators back to kidney school ;-) #nephjc |
| Arvind Canchi (Conjeevaram)🇮🇳 @arvindcanchi RT @ChristosArgyrop: @kidney_boy 1. About 40%-50% of DKD in modern era will be minimally proteinuric 2. RAASi work #NephJC https://t.co/OXt1VhmjRt (for 1st point) |
| Nephrology Journal Club @NephJC Also, ~ 9% in Cana group had reduction in DM meds, hence the lines tend to converge with time (for HgbA1c) #nephjc |
| ChristosArgyropoulos MD, PhD PharmanukerInChief @ChristosArgyrop @RossNesbit @NephJC Modern DKD is non proteinuric in 50% of cases. #nephjc |
| Joel M. Topf, MD FACP @kidney_boy @ottawamarble @Nephro_Sparks @drjjw which serum ketones did you measure? #nephjc |
| Nephrology Journal Club @NephJC RT @VladoPerkovic: @kidney_boy nephropathy is an investigator check box- macroalbuminuria measured at screening visit #NephJC |
| Edgar V. Lerma 🇵🇭 @edgarvlermamd CANVAS: Canagliflozin and CV & Renal Events in Type 2 DM ✅ A1C ✅ BP ✅ Weight loss #NephJC #Nephpearls 👉🏼 https://t.co/HKVWivq1nU https://t.co/9nm5uYskuJ |
| Nephrology Journal Club @NephJC T2: more on renal baseline data here #NephJC https://t.co/Q5nQ65rG4y |
| Gates Colbert, MD @DoctorGates @Maximal_Change @NephJC #UtilityDrug. The friend everyone likes at a party, but he gets too rowdy and ruins everything sometimes #NephJC |
| ChristosArgyropoulos MD, PhD PharmanukerInChief @ChristosArgyrop @NephJC Too small of a % to make a difference. But drop in the eGFR will improve diabetic control and this happened in the PBO arm #NephJC |
| The George Institute for Global Health @georgeinstitute RT @NephJC: T2: T2: more on renal baseline data here #NephJC https://t.co/Q5nQ65rG4y |
| Matthew Sparks, MD @Nephro_Sparks @kidney_boy @ottawamarble @drjjw good q #KetoneSchmeetone #NephJC |
| Timothy Yau @Maximal_Change This reminds me of basically everyone I knew in high school. #nephJC https://t.co/e0WGD91lfh |
| Matthew Sparks, MD @Nephro_Sparks #NephJC https://t.co/kDWFxNm03A |
| ChristosArgyropoulos MD, PhD PharmanukerInChief @ChristosArgyrop Personally more likely to prescribe SGLT2i on severe proteinuria despite RAASi (small subgroup of this study) #NephJC https://t.co/e5UqXAKLdS |
| Edgar V. Lerma 🇵🇭 @edgarvlermamd CANVAS: Canagliflozin and CV & Renal Events in Type 2 DM ✅ Cardioprotective ✅ Renoprotective #NephJC #Nephpearls 👉🏼 https://t.co/HKVWivq1nU https://t.co/TB8OoTf5D9 |
| Nephrology Journal Club @NephJC T2: Ok - main outcomes Reduction in MACE (non-inferior and superior) Not in mortality so p values stop #NephJC https://t.co/MOqSmqwnAK |
| Timothy Yau @Maximal_Change Would you prescribe this in a CKD3 pt with diabetic nephropathy? What GFR would you say is too low? #nephjc |
| Edgar V. Lerma 🇵🇭 @edgarvlermamd SGLT2 inhibitors' ✅ beneficial effect on #Cardiorenal syndrome #NephJC #Nephpearls 👉🏼 https://t.co/oAxXdocsnc https://t.co/6USEW4SEOp |
| Joel M. Topf, MD FACP @kidney_boy @Maximal_Change cooler friends than me. My friends, we played a lot of D&D #nephjc |
| George Clinical @george_clinical RT @NephJC: T2: T2: more on renal baseline data here #NephJC https://t.co/Q5nQ65rG4y |
| Timothy Yau @Maximal_Change Me too. Warhammer, Shadowrun, D and D....there was nothing too nerdy for me. Except I never cosplayed. Never. #nephJC https://t.co/g3edR4AhSP |
| Edgar V. Lerma 🇵🇭 @edgarvlermamd CANVAS: Canagliflozin and CV & Renal Events in Type 2 DM ‼️ Amputations ‼️ Fractures #NephJC #Nephpearls 👉🏼 https://t.co/HKVWiv8qwm https://t.co/oYyJWfok5l |
| Arvind Canchi (Conjeevaram)🇮🇳 @arvindcanchi @tukaramj Good morning @tukaramj #nephJC |
| Timothy Yau @Maximal_Change @tukaramj Welome! What time is it there now? 9 am? #nephjc |
| Nephrology Journal Club @NephJC T2: lot of subgroup data Mostly interaction p values NS (incl CKD stage) except diuretic Beta-blocker use #NephJC https://t.co/uWWbzh0ygN |
| Dr. Jordan Weinstein @drjjw #Nephjc https://t.co/HrdcWO8gFQ |
| Nephrology Journal Club @NephJC RT @ChristosArgyrop: Personally more likely to prescribe SGLT2i on severe proteinuria despite RAASi (small subgroup of this study) #NephJC https://t.co/e5UqXAKLdS |
 | Muna Islami @muna_islami RT @edgarvlermamd: Canagliflozin and CV & Renal Events in Type 2 DM #VisualAbstract #NephJC #Nephpearls 👉🏼 https://t.co/zm8nraaxg1 https://t.co/E79nGygral |
| Nephrology Journal Club @NephJC @arvindcanchi @tukaramj nice to see you Tukaram! (and great blog) #nephjc |
| Dr. Jordan Weinstein @drjjw @NephJC The diuretic interaction was not seen in empa-reg #NephJC |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil RT @NephJC: T2: T2: Ok - main outcomes Reduction in MACE (non-inferior and superior) Not in mortality so p values stop #NephJC https://t.co/MOqSmqwnAK |
| Mana @manasigh RT @edgarvlermamd: SGLT2 inhibitors' ✅ beneficial effect on #Cardiorenal syndrome #NephJC #Nephpearls 👉🏼 https://t.co/oAxXdocsnc https://t.co/6USEW4SEOp |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil RT @NephJC: T2: T2: lot of subgroup data Mostly interaction p values NS (incl CKD stage) except diuretic Beta-blocker use #NephJC https://t.co/uWWbzh0ygN |
| Nephrology Journal Club @NephJC How does the CV outcome compare with EMPAREG? Not bad - mostly overlapping #NephJC https://t.co/3F7pzNgujs |
| Arvind Canchi (Conjeevaram)🇮🇳 @arvindcanchi @Maximal_Change @tukaramj 7am! #NephJC |
| Mana @manasigh RT @edgarvlermamd: CANVAS: CANVAS: Canagliflozin and CV & Renal Events in Type 2 DM ✅ Cardioprotective ✅ Renoprotective #NephJC #Nephpearls 👉🏼 https://t.co/HKVWivq1nU https://t.co/TB8OoTf5D9 |
| Nephrology Journal Club @NephJC RT @drjjw: @NephJC The diuretic interaction was not seen in empa-reg #NephJC |
| Hector Madariaga, MD FASN 🇲🇽 @HecmagsMD #NephJC https://t.co/9LJc4tWvmy |
| Dr. Jordan Weinstein @drjjw @Nephro_Sparks @ottawamarble @kidney_boy Yes if the gap matches the degree of MA. Often we don't get ketone quantity. So other acids possible #NephJC |
| The George Institute for Global Health @georgeinstitute RT @NephJC: How does the CV outcome compare with EMPAREG? Not bad - mostly overlapping #NephJC https://t.co/3F7pzNgujs |
| Timothy Yau @Maximal_Change @arvindcanchi @tukaramj Props for joining! I'm still asleep then if I have the choice :) #nephjc |
| Nephrology Journal Club @NephJC OK - since this is #NephJC, lets see the renal outcomes a bit closely #nephjc |
| Edgar V. Lerma 🇵🇭 @edgarvlermamd Key Outcomes in CANVAS vs EMPA-REG OUTCOME 🥊 #NephJC #Nephpearls 👉🏼 https://t.co/HKVWivq1nU https://t.co/jq2L6g5M8k |
| Ross Nesbit @RossNesbit @NephJC Is the beta blockade enough of a protector for MI/CV events to explain it's apparent benefit? #nephjc |
| Matthew Sparks, MD @Nephro_Sparks @drjjw @ottawamarble @kidney_boy sometimes BetaHB takes a while to come back. but need meticulous measurements me thinks #NephJC |
| Nephrology Journal Club @NephJC Here is change in ACR with time (continuous) #NephJC https://t.co/a70Nr9Emgj |
| ChristosArgyropoulos MD, PhD PharmanukerInChief @ChristosArgyrop @NephJC Two interpr: 1) drugs works better in sicker pts with more severe CVD 2) it'ss the volume overload+RAAS activation you stupid 😉 #Nephjc |
| Nephrology Journal Club @NephJC RT @RossNesbit: @NephJC Is the beta blockade enough of a protector for MI/CV events to explain it's apparent benefit? #nephjc |
| Dr. Jordan Weinstein @drjjw @NephJC @georgeinstitute @george_clinical And remember this was a lower risk group so harder to show reductions in events (think PEACE versus HOPE or EUROPA) #Nephjc |
| Nephrology Journal Club @NephJC And here's regression/progression of albuminuria (part of composite renal outcome) #NephJC https://t.co/n1xRVvOlUS |
| Nephrology Journal Club @NephJC RT @ChristosArgyrop: @NephJC Two interpr: @NephJC Two interpr: 1) drugs works better in sicker pts with more severe CVD 2) it'ss the volume overload+RAAS activation you stupid 😉 #Nephjc |
| Dr. Jordan Weinstein @drjjw RT @Nephro_Sparks: @drjjw @ottawamarble @kidney_boy sometimes BetaHB takes a while to come back. but need meticulous measurements me thinks #NephJC |
| Nephrology Journal Club @NephJC RT @drjjw: @NephJC @georgeinstitute @george_clinical And remember this was a lower risk group so harder to show reductions in events (think PEACE versus HOPE or EUROPA) #Nephjc |
| Edgar V. Lerma 🇵🇭 @edgarvlermamd MT @CharlieTomson MARK: Summary of CV outcome trials with SGLT2 inhibitors #UKKW2017 🇬🇧 #Nephpearls #NephJC https://t.co/u8Hz4tB3p4 |
| Hector Madariaga, MD FASN 🇲🇽 @HecmagsMD RT @NephJC: How does the CV outcome compare with EMPAREG? Not bad - mostly overlapping #NephJC https://t.co/3F7pzNgujs |
 | Felix_Dantès @Felix_Dantes RT @NephJC: How does the CV outcome compare with EMPAREG? Not bad - mostly overlapping #NephJC https://t.co/3F7pzNgujs |
| George Clinical @george_clinical RT @NephJC: How does the CV outcome compare with EMPAREG? Not bad - mostly overlapping #NephJC https://t.co/3F7pzNgujs |
| Matthew Sparks, MD @Nephro_Sparks @NephJC those ACRs would NOT impress me... I get the difference but whoaa that is not much #nephjc |
| Nephrology Journal Club @NephJC And last: composite renal outcome #NephJc Only 21 dialysis or renal death https://t.co/8ilIqA6Lyr |
| ChristosArgyropoulos MD, PhD PharmanukerInChief @ChristosArgyrop @NephJC @georgeinstitute @george_clinical Seems the effect is established early - slope difference much less impressive #NephJC |
| Joel M. Topf, MD FACP @kidney_boy Is this something I could interest you in? #NephJC https://t.co/aGKw4fvPjE |
| Hector Madariaga, MD FASN 🇲🇽 @HecmagsMD This is a great slide! #NephJC https://t.co/EoJwux68Kf |
| Michelle Rheault @rheault_m @NephJC I kind of have a philosophical problem with microalb->macroalb and no alb -> microalbuminuria being considered same outcome #NephJC |
| Nephrology Journal Club @NephJC RT @Nephro_Sparks: @NephJC those ACRs would NOT impress me... I get the difference but whoaa that is not much #nephjc |
| Matthew Sparks, MD @Nephro_Sparks I guess I need to stop knocking the mouse studies showing barely anything and barely barely anything #nephjc |
| Nephrology Journal Club @NephJC RT @rheault_m: @NephJC I kind of have a philosophical problem with microalb->macroalb and no alb -> microalbuminuria being considered same outcome #NephJC |
| Michelle Rheault @rheault_m @NephJC But I know that's a standard diabetes trial thing. #NephJC |
 | tukaram @tukaramj RT @rheault_m: @NephJC I kind of have a philosophical problem with microalb->macroalb and no alb -> microalbuminuria being considered same outcome #NephJC |
| Ross Nesbit @RossNesbit Correct me if wrong...didn't EMPA-REG stop progression/decrease incidence of new MA/proteinuria? #nephjc |
 | transplantrockstar (he/him) @tx_rockstar RT @NephJC: How does the CV outcome compare with EMPAREG? Not bad - mostly overlapping #NephJC https://t.co/3F7pzNgujs |
 | محذوف @milardport RT @NephJC: We are discussing this @NEJM RCT, funded by @JanssenUS & carried out by @georgeinstitute https://t.co/NGzyaiq1tC #NephJC |
| Nephrology Journal Club @NephJC Did anyone see if RAS blockade use across trial follow up different? (would be unlikely since BP lower with Cana anyways, but...) #nephjc |
| Dr. Jordan Weinstein @drjjw +1M https://t.co/xrN1wxn5PA |
| The George Institute for Global Health @georgeinstitute RT @NephJC: And last: And last: composite renal outcome #NephJc Only 21 dialysis or renal death https://t.co/8ilIqA6Lyr |
| ChristosArgyropoulos MD, PhD PharmanukerInChief @ChristosArgyrop @Nephro_Sparks @NephJC Worth remembering that these are on top of RAASi. Still I would have liked to see analysis looking at baseline (+ f/u use of RAASi) #NephJC |
| Nephrology Journal Club @NephJC RT @ChristosArgyrop: @NephJC @georgeinstitute @george_clinical Seems the effect is established early - slope difference much less impressive #NephJC |
| Dr. Jordan Weinstein @drjjw RT @rheault_m: @NephJC I kind of have a philosophical problem with microalb->macroalb and no alb -> microalbuminuria being considered same outcome #NephJC |
| George Clinical @george_clinical RT @NephJC: And last: And last: composite renal outcome #NephJc Only 21 dialysis or renal death https://t.co/8ilIqA6Lyr |
| Nephrology Journal Club @NephJC Good Q for @VladoPerkovic #nephjC https://t.co/6K1mardToe |
| Joel M. Topf, MD FACP @kidney_boy #NephJC https://t.co/vZUzV2Ef5q |
| Timothy Yau @Maximal_Change @HecmagsMD @EdgarVLermaMD. When are CREDENCE results due? Renal primary outcome is most salient to us. #nephjc |
| Matthew Sparks, MD @Nephro_Sparks @RossNesbit thought it was new incidence of MA/protein... not progression #NephJC #EmpaReg |
| rob @renalpolitics #nephjc significant regression of proteinuria on placebo speaks likely 2 bp control but also its poor function as risk marker, best we got |
| ChristosArgyropoulos MD, PhD PharmanukerInChief @ChristosArgyrop @NephJC I did not see it #nephjc |
| Nephrology Journal Club @NephJC OK - time flying, lets quickly talk of adverse events #nephjc |
| Ross Nesbit @RossNesbit @Nephro_Sparks @RossNesbit Sorry I misworded that...didn't progress TO MA/proteinuria; it prevented development of MA/macro? #nephjc |
| Dr. Jordan Weinstein @drjjw @Maximal_Change @HecmagsMD @edgarvlermamd 1-2 years #Nephjc |
| Timothy Yau @Maximal_Change @NephJC I get the urogenital infections. Don't understand the physiologic explanation for the amputations at all. #nephjc |
| Nephrology Journal Club @NephJC Adverse events Started looking for DKA as RCT on & DSMB asked to look for amputation! #NephJC https://t.co/Csk7E6Djb8 |
| Edgar V. Lerma 🇵🇭 @edgarvlermamd CANVAS: Canagliflozin and CV & Renal Events in Type 2 DM ✅ A1C ✅ BP ✅ Weight loss ✅ UACR #NephJC #Nephpearls 👉🏼 https://t.co/HKVWivq1nU https://t.co/9ftIOnOPJv |
| Timothy Yau @Maximal_Change @NephJC The fractures seem weird - why such drastic differences b/w CANVAS and CANVAS-R? #nephjc |
| Dr. Jordan Weinstein @drjjw @Maximal_Change @NephJC I also don't buy the amputations :) #nephjc |
| Nephrology Journal Club @NephJC @Nephro_Sparks @RossNesbit right, see Joel's summary https://t.co/k69ARWpPrN #nephjc |
| Mana @manasigh RT @edgarvlermamd: SGLT2 inhibitors: SGLT2 inhibitors: Renoprotective #NephJC #Nephpearls 👉🏼 https://t.co/HKVWivq1nU https://t.co/hq6j58AG7g |
| Nephrology Journal Club @NephJC @Maximal_Change @NephJC the DSMB asked for it...they picked it up #nephjc |
| Mana @manasigh RT @edgarvlermamd: SGLT2 inhibitors: SGLT2 inhibitors: Cardioprotective #NephJC #Nephpearls 👉🏼 https://t.co/HKVWiv8qwm https://t.co/WZzN7kOONy |
| Timothy Yau @Maximal_Change @drjjw @NephJC You my friend are a hard sell :) #nephjc |
| The George Institute for Global Health @georgeinstitute RT @NephJC: Adverse events Started looking for DKA as RCT on & DSMB asked to look for amputation! #NephJC https://t.co/Csk7E6Djb8 |
| Matthew Sparks, MD @Nephro_Sparks great chat all. I'm out. will catch rest on storify. love to see the passion 4 knowledge. pushing the envelope of science. #LoveIt #nephjc |
| Timothy Yau @Maximal_Change @Nephro_Sparks See ya Matt, take care. #nephjc |
| Nephrology Journal Club @NephJC So here's infections: up as expected #NephJC https://t.co/JJKDlu2MET |
| Nephrology Journal Club @NephJC More on infections, osmotic diuresis #NephJC https://t.co/vEc3IkG08U |
| ChristosArgyropoulos MD, PhD PharmanukerInChief @ChristosArgyrop @Maximal_Change @NephJC There may be a credible mechanisms - SGLT2i have differential effects on oxidative phosphorylation #NephJC |
| Edgar V. Lerma 🇵🇭 @edgarvlermamd @Maximal_Change @HecmagsMD See this table from @PSNkidney 2014 Annual Meeting - Dr Wanner presenting about SGLT2 inhibitor trials #NephJC https://t.co/HBWinU271X |
| Nephrology Journal Club @NephJC And, drumroll: the amputations Mostly toes, but also more major (consistent) #NephJC https://t.co/r4pnZOaiVq |
| Mana @manasigh RT @edgarvlermamd: Currently FDA approved SGLT2 inhibitors #NephJC #Nephpearls 👉🏼 https://t.co/cKcWms9j0Y https://t.co/jd1EHUyvRD |
| Gates Colbert, MD @DoctorGates What is your preference of bodily harm from CANVAS? From @hswapnil #nephjc |
| Nephrology Journal Club @NephJC RT @ChristosArgyrop: @Maximal_Change @NephJC There may be a credible mechanisms - SGLT2i have differential effects on oxidative phosphorylation #NephJC |
| ChristosArgyropoulos MD, PhD PharmanukerInChief @ChristosArgyrop 1. Different time periods (lots of deprescribing of biphosphonates recently) 2. different doses #NephJC https://t.co/CWm7ayW9xu |
| Ross Nesbit @RossNesbit @ChristosArgyrop @Maximal_Change @NephJC Would similar off-target effect explain why VTE was a pre-specified AE? #nephjc |
| Timothy Yau @Maximal_Change @edgarvlermamd @HecmagsMD @PSNkidney Still 2+ years away then. Thanks! #NephJC |
| Edgar V. Lerma 🇵🇭 @edgarvlermamd @NephJC @georgeinstitute @george_clinical MT @ERAEDTA WANNER: EMPA-REG OUTCOME - Renal and CV Outcomes #VisualAbstract at #ERAEDTA17 🇪🇸 #Nephpearls #NephJC https://t.co/2YTo5A2CxI |
| Joel M. Topf, MD FACP @kidney_boy @NephJC @georgeinstitute @george_clinical What does osmotic diuresis mean here? Shouldn't it be 100%? #NephJC |
| Nephrology Journal Club @NephJC And for amputation from Cana: not explained by PVD history, or other factors examined #NephJC https://t.co/MNOyFjDbhs |
| Ross Nesbit @RossNesbit @NephJC Didn't see this as a baseline characteristic; would wonder if placebo group had more/less amputation at baseline? #nephjc |
| Dr. Jordan Weinstein @drjjw #Nephjc https://t.co/acUr1S9Psy |
| Nephrology Journal Club @NephJC RT @ChristosArgyrop: 1. Different time periods (lots of deprescribing of biphosphonates recently) 2. different doses #NephJC https://t.co/CWm7ayW9xu |
| Michael Fralick @FralickMike @drjjw @Maximal_Change @NephJC you power an RCT for efficacy. you don't power it for an adverse events. #nephjc |
| محذوف @milardport RT @NephJC: T0 follow up: T0 follow up: Have you seen any patient with SGLT2 & a complication? (Eg DKA or urogenital infxn) #NephJC |
| محذوف @milardport RT @NephJC: T - 10 minutes. Anyone here? #nephjc |
| Timothy Yau @Maximal_Change @ChristosArgyrop @NephJC I believe you, but when anyone says those words it sounds like code for "I don't really know" #nephjc |
| tukaram @tukaramj Makes sense to hold/decrease RASi before start? https://t.co/4v3kmBrJG4 |
| Nephrology Journal Club @NephJC @RossNesbit @NephJC no diff in PVD, and not explained by that.. #nephjc |
| Timothy Yau @Maximal_Change @ChristosArgyrop @NephJC I also get that feeling when anyone says "oxidative stress" or "free radical formation" #nephjc |
| Dr. Jordan Weinstein @drjjw @FralickMike @Maximal_Change @NephJC I realize. But if you measure unlimited outcomes will you not see things by chance? Absolutely will. #nephjc |
| Nephrology Journal Club @NephJC Important slide to put it all together Benefit + risk #NephJC https://t.co/LWPCFj21Eu |
| محذوف @milardport RT @NephJC: #NephJC https://t.co/dspgmOrrjh |
| محذوف @milardport RT @NephJC: #NephJC https://t.co/a8KFvWcLun |
| محذوف @milardport RT @NephJC: OK - lets move on to results since there are lots of them #nephjc |
| Nephrology Journal Club @NephJC @Nephro_Sparks see you later matt! thx for coming #nephjc |
| Ross Nesbit @RossNesbit @NephJC @RossNesbit Well PVD could mean abnormal ABI, claudication. But if already amputated there's nothing left to cut. #nephjc |
| The George Institute for Global Health @georgeinstitute RT @NephJC: Important slide to put it all together Benefit + risk #NephJC https://t.co/LWPCFj21Eu |
| Nephrology Journal Club @NephJC RT @RossNesbit: @NephJC @RossNesbit Well PVD could mean abnormal ABI, claudication. But if already amputated there's nothing left to cut. #nephjc |
| Joel M. Topf, MD FACP @kidney_boy @drjjw @FralickMike @Maximal_Change @NephJC Adverse events are too important to ignore. Need to look into this. #NephJC |
| محذوف @milardport RT @NephJC: T1: contd: T1: contd: plan changed to add-on CANVAS-R. See https://t.co/lC3drl8996 for details #NephJC https://t.co/yQ4PaX1vCS |
| محذوف @milardport RT @NephJC: T1: Population type 2 DM with GFR > 30 Age > 30 with CV dz or Age > 50 with 2 or more CV risk factors #NephJC |
| محذوف @milardport RT @NephJC: T2: T2: table 1, 14 years DM, ~ in 60s, mostly white, anything else strike you? #NephJC https://t.co/csFphxbLOU |
| محذوف @milardport RT @NephJC: Did you sense some unhappiness with the unblinding for approval? Or a pragmatic decision? #nephjc |
| Timothy Yau @Maximal_Change RT @NephJC: Important slide to put it all together Benefit + risk #NephJC https://t.co/LWPCFj21Eu |
| William Beaubien-Souligny @WBeaubien @NephJC Seen one with acute pyelonephritis, might have been a simple coincidence? #nephjc |
| محذوف @milardport RT @NephJC: T1: T1: plan was for CANVAS phase 1 f/b expansion to phase 2 with 14,000 Interim results used sponsor, so 1/2 #NephJC https://t.co/eElLkPVmPb |
| محذوف @milardport RT @NephJC: T1: T1: non-inferiority design, mostly from FDA requireemnt to show CV safety (after rosiglitazone mess) https://t.co/6pF6hdPCyF #nephjc |
| محذوف @milardport RT @NephJC: Welcome to the oh-so-sweet edition of #NephJC on #CANVAS Summary here: https://t.co/ioILbQeWIk |
| محذوف @milardport RT @NephJC: T1: T1: strict hierarchy of outcomes since CANVAS-R added in. Looks robust, agree? #NephJC https://t.co/Ii49HQCn7k |
| Joel M. Topf, MD FACP @kidney_boy RT @NephJC: Important slide to put it all together Benefit + risk #NephJC https://t.co/LWPCFj21Eu |
| tukaram @tukaramj RT @NephJC: Important slide to put it all together Benefit + risk #NephJC https://t.co/LWPCFj21Eu |
| محذوف @milardport RT @NephJC: T1: T1: also note, though controls = placebo, background of std of care for glucose, BP, CV mgt etc #NephJC |
| محذوف @milardport RT @NephJC: Just over an hour left for tonight's #NephJC Not too late to read the article or the summary. Or just use the #VisualAbstract to wing it! |
| ChristosArgyropoulos MD, PhD PharmanukerInChief @ChristosArgyrop @Maximal_Change @NephJC See these https://t.co/unLbXqvwDZ https://t.co/xv52kJXtaO #NephJC Ppl have experimented with antitumor activity based on these #NephJC |
| Dr. Jordan Weinstein @drjjw #Nephjc https://t.co/qqDDLqT5v3 |
| محذوف @milardport RT @NephJC: T1: T1: methods Let's dive in. CANVAS program = CANVAS + CANVAS-R Everyone OK with how that played out? #NephJC https://t.co/WDhjjq2Ia4 |
| محذوف @milardport RT @NephJC: (Acknowledgment: Lot of material directly from @george_clinical website: (Acknowledgment: Lot of material directly from @george_clinical website: https://t.co/swGfh9uGqn) #NephJC |
| Nephrology Journal Club @NephJC Also, Cana: More renal adverse events (though p NS) And more fractures too #NephJC https://t.co/cvjZjn0Hl6 |
| Nephrology Journal Club @NephJC RT @ChristosArgyrop: @Maximal_Change @NephJC See these https://t.co/unLbXqvwDZ https://t.co/xv52kJXtaO #NephJC Ppl have experimented with antitumor activity based on these #NephJC |
| George Clinical @george_clinical RT @NephJC: Important slide to put it all together Benefit + risk #NephJC https://t.co/LWPCFj21Eu |
| Edgar V. Lerma 🇵🇭 @edgarvlermamd @Maximal_Change @ChristosArgyrop @NephJC What scientists 🔬 say in research papers vs. What they actually mean #NephJC 👉🏼 https://t.co/QPclG8Q4mq… via @io9 https://t.co/X7hlYtq8rk |
| محذوف @milardport RT @NephJC: Lots of additional material at the @georgeinstitute website freely available https://t.co/swGfh9uGqn #NephJC |
| Nephrology Journal Club @NephJC RT @kidney_boy: @drjjw @FralickMike @Maximal_Change @NephJC Adverse events are too important to ignore. Need to look into this. #NephJC |
| محذوف @milardport RT @NephJC: Warm up question T0 do you use SGLT2 inhibitors already? if yes, for whom? If no, why not? #NephJC |
| Michael Fralick @FralickMike @drjjw @kidney_boy @Maximal_Change @NephJC yes, but just because we don't know the physiology now doesn't mean it's not a real adverse event. #nephjc effect size and CI impressive |
| Nephrology Journal Club @NephJC #NephJC lots of questions https://t.co/Pl0AGwqIqw |
 | Franklin Loachamin @FranLoachamin RT @edgarvlermamd: @Maximal_Change @ChristosArgyrop @NephJC What scientists 🔬 say in research papers vs. What they actually mean #NephJC 👉🏼 https://t.co/QPclG8Q4mq… via @io9 https://t.co/X7hlYtq8rk |
| Franklin Loachamin @FranLoachamin RT @NephJC: Also, Cana: Also, Cana: More renal adverse events (though p NS) And more fractures too #NephJC https://t.co/cvjZjn0Hl6 |
 | Dr. Vanessa Grubbs (she/her) @thenephrologist RT @gratefull080504: Use your #patientvoice and contact Congress Tell them funding #ckd research is a #publichealth priority https://t.co/aQjfkVRZDH #nephJC |
| Timothy Yau @Maximal_Change @ChristosArgyrop @NephJC fascinating, thanks for the link. was not aware at all #nephJC |
| Franklin Loachamin @FranLoachamin RT @kidney_boy: @drjjw @FralickMike @Maximal_Change @NephJC Adverse events are too important to ignore. Need to look into this. #NephJC |
| Joel M. Topf, MD FACP @kidney_boy @FralickMike @drjjw @Maximal_Change @NephJC Why do you think they didn't pick up a DKA signal here? #NephJC |
| Michael Fralick @FralickMike @kidney_boy @drjjw @Maximal_Change @NephJC Our group is looking into this. I'm programming a cohort of about 50K pts. But I'm not sure it will be enough to convince @drjjw #nephjc |
| Dr. Jordan Weinstein @drjjw It's certainly possible. But again, in a large study with unlimited measurements, you will find something by chance #nephjc https://t.co/j5qp9S8eBF |
| ChristosArgyropoulos MD, PhD PharmanukerInChief @ChristosArgyrop @NephJC Again some data from a poster in #SOT2017 #nephjc I think less is more with SGLT2i but esp with cana #NephJC https://t.co/4U1JigAcv9 |
| Nephrology Journal Club @NephJC Other pharmacokinetic differences between SGLT agents from https://t.co/nMhtVauHVi #NephJc https://t.co/HyMB9pa5r6 |
| محذوف @milardport RT @NephJC: T2: T2: so what did Cana do? Reduce sugar, BP and weight from figure 2 #NephJC https://t.co/95f2VJcALk |
| محذوف @milardport RT @DoctorGates: Small number of PVD - 20%, large CAD though. Possibly undetected PVD which could have confounded amputation surprise attack? #NephJC https://t.co/aIiRYCa0PF |
| Franklin Loachamin @FranLoachamin RT @edgarvlermamd: @NephJC @georgeinstitute @george_clinical MT @ERAEDTA WANNER: @NephJC @georgeinstitute @george_clinical MT @ERAEDTA WANNER: EMPA-REG OUTCOME - Renal and CV Outcomes #VisualAbstract at #ERAEDTA17 🇪🇸 #Nephpearls #NephJC https://t.co/2YTo5A2CxI |
| Franklin Loachamin @FranLoachamin RT @NephJC: More on infections, osmotic diuresis #NephJC https://t.co/vEc3IkG08U |
| Franklin Loachamin @FranLoachamin RT @NephJC: So here's infections: So here's infections: up as expected #NephJC https://t.co/JJKDlu2MET |
| Franklin Loachamin @FranLoachamin RT @Maximal_Change: @NephJC The fractures seem weird - why such drastic differences b/w CANVAS and CANVAS-R? #nephjc |
| ChristosArgyropoulos MD, PhD PharmanukerInChief @ChristosArgyrop @NephJC Yes - I think the higher dose of the SGLT2i have issues. Cant resolve without advanced PKPD modeling followed by more studies #NephJC |
| Franklin Loachamin @FranLoachamin RT @Maximal_Change: @NephJC I get the urogenital infections. Don't understand the physiologic explanation for the amputations at all. #nephjc |
| rob @renalpolitics #nephjc in end, is it good enough to add to metformin and RASi while focusing on diet as well!?! Assuming GFR ok. |
| Nephrology Journal Club @NephJC RT @ChristosArgyrop: @NephJC Again some data from a poster in #SOT2017 #nephjc I think less is more with SGLT2i but esp with cana #NephJC https://t.co/4U1JigAcv9 |
| Joel M. Topf, MD FACP @kidney_boy @renalpolitics still waiting for the renal data, but I'm a believer. #nephjc |
| Nephrology Journal Club @NephJC @kidney_boy @FralickMike @drjjw @Maximal_Change More seen, just not significant (twice as high) #NephJC https://t.co/gLzyApEtmI |
| Timothy Yau @Maximal_Change @renalpolitics IMO it is. #nephjc |
| Franklin Loachamin @FranLoachamin RT @RossNesbit: Correct me if wrong...didn't EMPA-REG stop progression/decrease incidence of new MA/proteinuria? #nephjc |
| Edgar V. Lerma 🇵🇭 @edgarvlermamd SGLT2 inhibitors: Dose adjustments in CKD #SCM16 #Nephpearls #NephJC Photo Credit: @HecmagsMD https://t.co/oLVFwBjpK8 |
| Ross Nesbit @RossNesbit @renalpolitics Feels like it to me. Within my purview to be the prescriber? Hard to say. But I'm very encouraged by them so far. #nephjc |
| Dr. Jordan Weinstein @drjjw @FralickMike @kidney_boy @Maximal_Change @NephJC I'm still not sure why you you have more confidence in a large retrospective cohort than systematic review of good RCT data #nephjc |
| Nephrology Journal Club @NephJC Last 4 minutes! What are take home messages? Will you use SGLT2i? If yes, Empa or Cana? #nephjc |
| Franklin Loachamin @FranLoachamin RT @edgarvlermamd: MT @CharlieTomson MARK: MT @CharlieTomson MARK: Summary of CV outcome trials with SGLT2 inhibitors #UKKW2017 🇬🇧 #Nephpearls #NephJC https://t.co/u8Hz4tB3p4 |
| Franklin Loachamin @FranLoachamin RT @HecmagsMD: This is a great slide! #NephJC https://t.co/EoJwux68Kf |
| Joel M. Topf, MD FACP @kidney_boy I'm really interested in giving this to people without DM but high CV risk to see if they get similar benefits. #nephjc |
| George Clinical @george_clinical RT @NephJC: @kidney_boy @FralickMike @drjjw @Maximal_Change More seen, just not significant (twice as high) #NephJC https://t.co/gLzyApEtmI |
| Ross Nesbit @RossNesbit @NephJC If "use" = encourage, then I think so. Still feel like the Rx should be domain of endocrine/primary mgr of DM. #nephjc |
| Nephrology Journal Club @NephJC @drjjw @FralickMike @kidney_boy @Maximal_Change For adverse events (safety data) phase 4 post marketing surveillance more robust #NephJC |
| Sabrina Natarajan @ottawamarble #NephJC https://t.co/rYbI0nkERf |
| Nephrology Journal Club @NephJC RT @RossNesbit: @NephJC If "use" = encourage, then I think so. Still feel like the Rx should be domain of endocrine/primary mgr of DM. #nephjc |
| Timothy Yau @Maximal_Change @kidney_boy Be careful...it might become like statins and will be EVERYWHERE. #nephjc |
| Nephrology Journal Club @NephJC Is it all the diuretic effect as @toates_19 alluded? If so, maybe nephrons should use them?? #nephjc |
| ChristosArgyropoulos MD, PhD PharmanukerInChief @ChristosArgyrop I am limited by what the insurance will allow and current label. So far, more empa than cana for me for these reasons #NephJC https://t.co/XmyDKzb5G8 |
| Nephrology Journal Club @NephJC RT @kidney_boy: I'm really interested in giving this to people without DM but high CV risk to see if they get similar benefits. #nephjc |
| Timothy Yau @Maximal_Change @NephJC Yes, in the rare patient that I see that has preserved GFR. As for which one, whichever is cheaper. #nephjc |
| Joel M. Topf, MD FACP @kidney_boy DKA in CANVAS: 10,142 people, 3.6 years, 18 cases of DKA, and 5 of them actually had type 1 DM. Not impressed. #nephjc |
| Dr. Jordan Weinstein @drjjw @FralickMike @kidney_boy @Maximal_Change @NephJC The quality of registration trials is often very high. Strictly adjudicated. Cannot say the same for retrospective cohorts #nephjc |
| Nephrology Journal Club @NephJC RCTs on the way: via @CharlieTomson at #UKKW2017 DAPA-CKD in non diabetic, also DECLARE N = 25,000 #NephJC https://t.co/ekryAd9lG4 |
| Edgar V. Lerma 🇵🇭 @edgarvlermamd SGLT2 inhibitors advantages and disadvantages ‼️ Add Amputations to list 😶 #SCM16 #Nephpearls #NephJC Photo Credit: @HecmagsMD https://t.co/LjjGFR9imm |
| ChristosArgyropoulos MD, PhD PharmanukerInChief @ChristosArgyrop Can be used to "cut" insulin by a ridiculous % - trick used by some patients and prescribers down here (off label and not by me) #nephjc https://t.co/3tn1AicKS3 |
| Nephrology Journal Club @NephJC RT @kidney_boy: DKA in CANVAS: DKA in CANVAS: 10,142 people, 3.6 years, 18 cases of DKA, and 5 of them actually had type 1 DM. Not impressed. #nephjc |
| Joel M. Topf, MD FACP @kidney_boy And no reason to think these won't work at low GFRs. In fact low GFR. Am I right? I want that trial! #nephjc |
| Nephrology Journal Club @NephJC RT @ChristosArgyrop: Can be used to "cut" insulin by a ridiculous % - trick used by some patients and prescribers down here (off label and not by me) #nephjc https://t.co/3tn1AicKS3 |
| Michelle Rheault @rheault_m @NephJC There's a pediatric RCT of Canagliflozin in the works for type 2 diabetes. #NephJC https://t.co/rwbjecwOKy |
 | Ravinder @rbanait RT @rojasfec: This pictorial will save some reading.... :-) https://t.co/eT8r7Q7c5q |
| Pablo Garcia @PabloGarciaMD Not yet. I will wait for more studies. Recently read DKA is a risk factor. #nephjc |
| Nephrology Journal Club @NephJC @kidney_boy will they work well with GFR <30? Need dose adjustment? #nephjc |
| Dr. Jordan Weinstein @drjjw But maybe a moot point. You have to survive to get DKA and amputations and these drugs help you do that. Need to use correctly tho #nephjc |
| Nephrology Journal Club @NephJC RT @PabloGarciaMD: Not yet. I will wait for more studies. Recently read DKA is a risk factor. #nephjc |
| tukaram @tukaramj Exematous DKD, with preserved GFR, willing to bear with cost, and risks https://t.co/m4gb2KZy3Y |
| ChristosArgyropoulos MD, PhD PharmanukerInChief @ChristosArgyrop @kidney_boy For sugar reduction nope. Butwe may be looking at "spooky action" (on the heart) "at a distance" so may work at lower eGFR #nephjc |
| Vlado Perkovic @VladoPerkovic @NephJC @drjjw @FralickMike @kidney_boy @Maximal_Change Post marketing surveillance uncontrolled therefore useful for rare SEs, but not for common outcomes #nephjc |
| Nephrology Journal Club @NephJC Phew. its past 10 pm. Maybe we didn't get to it all. Tahnks everyone, esp @vladoperkovic for joining #nephjc |
| Nephrology Journal Club @NephJC remember EU #NephJC pushed to next wednesday, June 28th (for #UKKW2017) |
| Pablo Garcia @PabloGarciaMD So many options available. The pharm companies are too involved something is not right. I will say "first, do no harm" for now. #nephjc |
| tukaram @tukaramj Replication before application https://t.co/cHeV7Cb4kQ |
 | FedUp @Dulce_Says RT @kidney_boy: DKA in CANVAS: DKA in CANVAS: 10,142 people, 3.6 years, 18 cases of DKA, and 5 of them actually had type 1 DM. Not impressed. #nephjc |
| Nephrology Journal Club @NephJC there is an #askASN next week with @maximal_change and @renalpolitics et al June 27th #nephjc |
| Joel M. Topf, MD FACP @kidney_boy Great chat! Thanks for the learning. Look for me to vomit this back up in Keynote form for the Michigan ACP in September #nephjc |
| Michael Fralick @FralickMike @drjjw @kidney_boy @Maximal_Change @NephJC Ouch! I can't convince you. But when risks are 2/1000 & y have a syst review of 10K pts,you might not find signal due to power alone #nephjc |
| ChristosArgyropoulos MD, PhD PharmanukerInChief @ChristosArgyrop @NephJC @VladoPerkovic Good night! Maybe we need to do a follow up - too big of a paper to cover in 1 hr #nephjc Over and out from New Mexico |
| Vlado Perkovic @VladoPerkovic @NephJC dont you mean less renal adverse events but NS?? #nephjc |
| Nephrology Journal Club @NephJC RT @RossNesbit: @renalpolitics Feels like it to me. Within my purview to be the prescriber? Hard to say. But I'm very encouraged by them so far. #nephjc |
| Sabrina Natarajan @ottawamarble @kidney_boy I would think little action on blood glucose in pts with low GFR but yes, maybe CV effects #nephjc |
| Nephrology Journal Club @NephJC RT @VladoPerkovic: @NephJC @drjjw @FralickMike @kidney_boy @Maximal_Change Post marketing surveillance uncontrolled therefore useful for rare SEs, but not for common outcomes #nephjc |
| Michael Fralick @FralickMike @VladoPerkovic @NephJC @drjjw @kidney_boy @Maximal_Change Completely agree. Post-marketing surveillance is good for hypothesis generation #nephjc |
| Nephrology Journal Club @NephJC @VladoPerkovic Oops - I stand corrected, less renal adverse events in Cana (despite osmotic diuresis, AKI not a concern) #NephJC |
| rob @renalpolitics RT @NephJC: there is an #askASN next week with @maximal_change and @renalpolitics et al June 27th #nephjc |
| Timothy Yau @Maximal_Change Great chat everyone, motivated to do some more reading. Thanks to all for your participation! #nephjc |
| Nephrology Journal Club @NephJC RT @ChristosArgyrop: @NephJC @VladoPerkovic Good night! Maybe we need to do a follow up - too big of a paper to cover in 1 hr #nephjc Over and out from New Mexico |
| Nephrology Journal Club @NephJC Want to remain connected - sign up for the weekly newsletter https://t.co/5aumn8qL85 #nephjc |
| Dr. Jordan Weinstein @drjjw @FralickMike @kidney_boy @Maximal_Change @NephJC I think there could be something there. Just not convinced. Either way, I treat SGLT2i as a SADMANS drug because of work like yours #nephjc |
| Gates Colbert, MD @DoctorGates Encouraging CV outcomes, time and Rx will show us the real story of adverse events. That's what keeps being a Physician interesting #nephjc |
| محذوف @milardport RT @NephJC: Also, ~ 9% in Cana group had reduction in DM meds, hence the lines tend to converge with time (for HgbA1c) #nephjc |
| Sabrina Natarajan @ottawamarble Thanks for the fun chat! Looking forward to getting some DKA data together to prove @drjjw wrong/right! #nephjc |
| Nephrology Journal Club @NephJC The numbers: 461 Tweets. 57 Participants. 1,275,944 Impressions. June 20th 2017. More #NephJC 📊 here https://t.co/45fujqtsuf? https://t.co/8IOp91JpHl |
| Nephrology Journal Club @NephJC RT @drjjw: @FralickMike @kidney_boy @Maximal_Change @NephJC I think there could be something there. Just not convinced. Either way, I treat SGLT2i as a SADMANS drug because of work like yours #nephjc |
| Michael Fralick @FralickMike @drjjw @kidney_boy @Maximal_Change @NephJC Knowing how skeptical u are of cohort studies, I'll take that as a compliment! lookn fwd to your skepticism of my next SGLT2paper ;) #nephjc |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil RT @NephJC: The numbers: The numbers: 461 Tweets. 57 Participants. 1,275,944 Impressions. June 20th 2017. More #NephJC 📊 here https://t.co/45fujqtsuf? https://t.co/8IOp91JpHl |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil RT @NephJC: @VladoPerkovic Oops - I stand corrected, less renal adverse events in Cana (despite osmotic diuresis, AKI not a concern) #NephJC |
| Dr. Jordan Weinstein @drjjw @FralickMike @kidney_boy @Maximal_Change @NephJC SADMANS #Nephjc https://t.co/CzP5rOpf7D |
| Michael Fralick @FralickMike RT @drjjw: @FralickMike @kidney_boy @Maximal_Change @NephJC SADMANS #Nephjc https://t.co/CzP5rOpf7D |
| Joel M. Topf, MD FACP @kidney_boy The numbers: 540 Tweets. 91 Participants. June 19th 2017. More #NephJC 📊 here https://t.co/TgbNWB15nS via @symplur |
| Dr. Jordan Weinstein @drjjw @FralickMike @kidney_boy @Maximal_Change @NephJC I'm a lowly nephrologist. You are a published @NEJM author. Ignore me. #Nephjc |
| Michael Fralick @FralickMike @drjjw @kidney_boy @Maximal_Change @NephJC Great chat all. The Nephro twitter presence is impressive. This was good fun #nephjc |
| محذوف @milardport RT @NephJC: T2: T2: Ok - main outcomes Reduction in MACE (non-inferior and superior) Not in mortality so p values stop #NephJC https://t.co/MOqSmqwnAK |
| محذوف @milardport RT @NephJC: T2: T2: lot of subgroup data Mostly interaction p values NS (incl CKD stage) except diuretic Beta-blocker use #NephJC https://t.co/uWWbzh0ygN |
 | Derek Leong @Derek_Leong_RPh RT @drjjw: @FralickMike @kidney_boy @Maximal_Change @NephJC SADMANS #Nephjc https://t.co/CzP5rOpf7D |
| Timothy Yau @Maximal_Change @FralickMike @drjjw @kidney_boy @NephJC Thanks so much for joining, was great to hear your input! #nephJC |
| محذوف @milardport RT @ChristosArgyrop: Personally more likely to prescribe SGLT2i on severe proteinuria despite RAASi (small subgroup of this study) #NephJC https://t.co/e5UqXAKLdS |
| Dr. Jordan Weinstein @drjjw That was utterly exhausting #nephjc |
| Dr. Jordan Weinstein @drjjw Who mans wo/manning the @NephJC handle tonight? #nephjc |
| محذوف @milardport RT @NephJC: OK - since this is #NephJC, lets see the renal outcomes a bit closely #nephjc |
| محذوف @milardport RT @NephJC: How does the CV outcome compare with EMPAREG? Not bad - mostly overlapping #NephJC https://t.co/3F7pzNgujs |
| محذوف @milardport RT @NephJC: And here's regression/progression of albuminuria (part of composite renal outcome) #NephJC https://t.co/n1xRVvOlUS |
| محذوف @milardport RT @ChristosArgyrop: @NephJC Two interpr: @NephJC Two interpr: 1) drugs works better in sicker pts with more severe CVD 2) it'ss the volume overload+RAAS activation you stupid 😉 #Nephjc |
| محذوف @milardport RT @drjjw: @NephJC @georgeinstitute @george_clinical And remember this was a lower risk group so harder to show reductions in events (think PEACE versus HOPE or EUROPA) #Nephjc |
| محذوف @milardport RT @Nephro_Sparks: @NephJC those ACRs would NOT impress me... I get the difference but whoaa that is not much #nephjc |
| محذوف @milardport RT @NephJC: And last: And last: composite renal outcome #NephJc Only 21 dialysis or renal death https://t.co/8ilIqA6Lyr |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil RT @kidney_boy: The numbers: The numbers: 540 Tweets. 91 Participants. June 19th 2017. More #NephJC 📊 here https://t.co/TgbNWB15nS via @symplur |
| محذوف @milardport RT @Nephro_Sparks: I guess I need to stop knocking the mouse studies showing barely anything and barely barely anything #nephjc |
| محذوف @milardport RT @rheault_m: @NephJC I kind of have a philosophical problem with microalb->macroalb and no alb -> microalbuminuria being considered same outcome #NephJC |
| Matthew Sparks, MD @Nephro_Sparks The numbers: 567 Tweets. 92 Participants. June 19th 2017. More #NephJC 📊 here https://t.co/fi2IYkvfrU via @symplur |
| Michael Fralick @FralickMike @drjjw @RSiemieniuk @kidney_boy @ottawamarble @Nephro_Sparks That's why we only looked at cases before the FDA warning and why we used an active comparator. but yes detection bias still possible#nephjc |
 | Manisha Dassi @manishadassi RT @AVATAROrg: Follow @AVATAROrg for the regular updates / LIVE Tweets AVATAR 2017 | 21-22 July, 2017 | The Lalit, Goa #NephAVATAR #SoMe #NephJC #AskRenal https://t.co/paAwPKwVRi |
| محذوف @milardport RT @NephJC: Adverse events Started looking for DKA as RCT on & DSMB asked to look for amputation! #NephJC https://t.co/Csk7E6Djb8 |
| محذوف @milardport RT @NephJC: OK - time flying, lets quickly talk of adverse events #nephjc |
| محذوف @milardport RT @NephJC: Good Q for @VladoPerkovic #nephjC https://t.co/6K1mardToe |
| محذوف @milardport RT @ChristosArgyrop: @NephJC @georgeinstitute @george_clinical Seems the effect is established early - slope difference much less impressive #NephJC |
| محذوف @milardport RT @NephJC: Did anyone see if RAS blockade use across trial follow up different? (would be unlikely since BP lower with Cana anyways, but...) #nephjc |
| محذوف @milardport RT @NephJC: @Nephro_Sparks @RossNesbit right, see Joel's summary https://t.co/k69ARWpPrN #nephjc |
| محذوف @milardport RT @Nephro_Sparks: @RossNesbit thought it was new incidence of MA/protein... not progression #NephJC #EmpaReg |
| محذوف @milardport RT @NephJC: So here's infections: So here's infections: up as expected #NephJC https://t.co/JJKDlu2MET |
| محذوف @milardport RT @NephJC: More on infections, osmotic diuresis #NephJC https://t.co/vEc3IkG08U |
| محذوف @milardport RT @NephJC: And, drumroll: And, drumroll: the amputations Mostly toes, but also more major (consistent) #NephJC https://t.co/r4pnZOaiVq |
| محذوف @milardport RT @ChristosArgyrop: @Maximal_Change @NephJC There may be a credible mechanisms - SGLT2i have differential effects on oxidative phosphorylation #NephJC |
| محذوف @milardport RT @NephJC: And for amputation from Cana: And for amputation from Cana: not explained by PVD history, or other factors examined #NephJC https://t.co/MNOyFjDbhs |
| محذوف @milardport RT @ChristosArgyrop: 1. Different time periods (lots of deprescribing of biphosphonates recently) 2. different doses #NephJC https://t.co/CWm7ayW9xu |
 | Dr. Divya Bajpai 🇮🇳 @divyaa24 RT @edgarvlermamd: @Maximal_Change @ChristosArgyrop @NephJC What scientists 🔬 say in research papers vs. What they actually mean #NephJC 👉🏼 https://t.co/QPclG8Q4mq… via @io9 https://t.co/X7hlYtq8rk |
| محذوف @milardport RT @NephJC: Important slide to put it all together Benefit + risk #NephJC https://t.co/LWPCFj21Eu |
| محذوف @milardport RT @NephJC: @Nephro_Sparks see you later matt! thx for coming #nephjc |
| محذوف @milardport RT @Nephro_Sparks: great chat all. I'm out. will catch rest on storify. love to see the passion 4 knowledge. pushing the envelope of science. #LoveIt #nephjc |
| محذوف @milardport RT @RossNesbit: @NephJC @RossNesbit Well PVD could mean abnormal ABI, claudication. But if already amputated there's nothing left to cut. #nephjc |
| محذوف @milardport RT @NephJC: Also, Cana: Also, Cana: More renal adverse events (though p NS) And more fractures too #NephJC https://t.co/cvjZjn0Hl6 |
| محذوف @milardport RT @ChristosArgyrop: @Maximal_Change @NephJC See these https://t.co/unLbXqvwDZ https://t.co/xv52kJXtaO #NephJC Ppl have experimented with antitumor activity based on these #NephJC |
| محذوف @milardport RT @kidney_boy: @drjjw @FralickMike @Maximal_Change @NephJC Adverse events are too important to ignore. Need to look into this. #NephJC |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil RT @ChristosArgyrop: @kidney_boy 1. About 40%-50% of DKD in modern era will be minimally proteinuric 2. RAASi work #NephJC https://t.co/OXt1VhmjRt (for 1st point) |
| محذوف @milardport RT @NephJC: #NephJC lots of questions https://t.co/Pl0AGwqIqw |
| محذوف @milardport RT @edgarvlermamd: @Maximal_Change @ChristosArgyrop @NephJC What scientists 🔬 say in research papers vs. What they actually mean #NephJC 👉🏼 https://t.co/QPclG8Q4mq… via @io9 https://t.co/X7hlYtq8rk |
| محذوف @milardport RT @NephJC: Other pharmacokinetic differences between SGLT agents from https://t.co/nMhtVauHVi #NephJc https://t.co/HyMB9pa5r6 |
#NephJC content from Twitter.